Study identifier:NIS-CRU-XXX-2011/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Long-tErm follow-uP of antithrombotic management patterns In Acute CORonary Syndrome patients in RUSsia
Acute Coronary Syndrome
N/A
No
-
All
600
Observational
18 Years - 99 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Mar 2015 by AstraZeneca
AstraZeneca
-
EPICOR-RUS is a multi-centre, observational, prospective, longitudinal cohort study which will include patients, in a real-life setting, who are hospitalized for acute coronary syndrome (ACS) within 24 hours of symptom onset and who have a final diagnosis of Unstable Angina (UA), ST-Elevation Myocardial Infarction (STEMI) or Non-ST-Elevation Myocardial Infarction (NSTEMI). Patients will undergo clinical assessments and receive the standard medical care as determined by the treating cardiologist. Patients will not receive experimental intervention or experimental treatment as a consequence of their participation in the EPICOR-RUS observational study.
Location
Location
Barnaul, Russian Federation
Location
Cheboksary, Russian Federation
Location
Ekaterinburg, Russian Federation
Location
Kazan, Russian Federation
Location
Kemerovo, Russian Federation
Location
Kirov, Russian Federation
Location
Krasnodar, Russian Federation
Location
Krasnoyarsk, Russian Federation
Arms | Assigned Interventions |
---|---|
1 Patients hospitalized and diagnosed with UA, STEMI or NSTEMI | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.